C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...
Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...
Atea Pharmaceuticals offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines the advantages of current first-line HCV therapies—single pill ...
WSAV-TV on MSN
Housing Authority to open HCV Program waiting list
The Housing Authority of Savannah (HAS) announced it will be opening its Section 8 Housing Choice Voucher (HCV) Program ...
Only about 40% of perinatally exposed infants were tested for hepatitis C virus (HCV), and less than 30% of eligible children ...
Injection drug use is both a potent risk factor for incarceration and the primary transmission route for hepatitis C virus (HCV) infections. Combining HCV testing and treatment in jails with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Annual courses of direct-acting antivirals for HCV have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results